Skip to main content
SpringerLink
Log in
Book cover

Chronic Myeloid Leukemia pp 99–110Cite as

Epidemiology of Chronic Myeloid Leukemia

  • Chapter
  • First Online:

  • 1555 Accesses

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

Abstract

National and regional population-based registries are, provided diagnostic accuracy and full coverage of the target population, indispensible tools for epidemiological research. CML registries with a more comprehensive reporting may also provide complementary data on treatment outcome to those obtained from clinical trials. Reports from several European CML registries consistently show a crude annual incidence of 0.7–1.3/100,000, median age at diagnosis of 56–60 years and a male/female ratio of 1.2–1.7. The incidence of CML has been stable over time. Worldwide, variations in reported incidence of CML may be due to methodological issues, but a true difference between different geographical areas and/or ethnical subgroups cannot be excluded. The prevalence of CML is less well known but has been estimated to 10–12/100,000 inhabitants with a steady increase due to the dramatic improvement in survival of these patients. In recent population-based studies, CML patients have an overall survival that is comparable to that shown in large clinical trials, though relative survival in patients >70 years is still decreased. The importance of socioeconomic factors and health-care setting for outcome, a possible increased risk of secondary cancer in CML and possible long-term adverse off-target effects related to the use of tyrosine kinase inhibitors, are areas of ongoing epidemiological research.

Parts of this chapter have formerly been published within the journal Annals of Hematology in Volume 94, Issue 2, supplement, April 2015, “Chronic Myeloid Leukemia”, doi:10.1007/s00277-015-2314-2.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Barlow L, Westergren K, Holmberg L, Talback M (2009) The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 48(1):27–33. doi:10.1080/02841860802247664

    Article  PubMed  Google Scholar 

  • Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Loffler H, Pralle H, Queisser W, Hehlmann R (2005) Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia Off J Leuk Soc Am Leuk Res Fund UK 19(6):984–989. doi:10.1038/sj.leu.2403756

    Article  CAS  Google Scholar 

  • Berglund A, Holmberg L, Tishelman C, Wagenius G, Eaker S, Lambe M (2010) Social inequalities in non-small cell lung cancer management and survival: a population-based study in central Sweden. Thorax 65(4):327–333. doi:10.1136/thx.2009.125914

    Article  PubMed  Google Scholar 

  • Bhayat F, Das-Gupta E, Smith C, McKeever T, Hubbard R (2009) The incidence of and mortality from leukaemias in the UK: a general population-based study. BMC Cancer 9:252. doi:10.1186/1471-2407-9-252

    Article  PubMed  PubMed Central  Google Scholar 

  • Bjorkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjoberg J, Andersson T, Hoglund M, Richter J, Landgren O, Kristinsson SY, Dickman PW (2011) Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 29(18):2514–2520. doi:10.1200/JCO.2011.34.7146

    Article  PubMed  PubMed Central  Google Scholar 

  • Bjorkholm M, Kristinsson SY, Landgren O, Goldin LR (2013) No familial aggregation in chronic myeloid leukemia. Blood 122(3):460–461. doi:10.1182/blood-2013-05-501312

    Article  PubMed  PubMed Central  Google Scholar 

  • Bjorkholm M, Bower H, Dickman PW, Lambert PC, Höglund M, Andersson TM-L (2016) Temporal trends in chronic myeloid leukemia outcome using the loss in expectation of life: a Swedish population-based study. J Clin Onocl 126(23):2779–2779

    Google Scholar 

  • Bray F, Parkin DM (2009) Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. Eur J Cancer 45(5):747–755. doi:10.1016/j.ejca.2008.11.032

    Article  PubMed  Google Scholar 

  • Breccia M, Alimena G (2013) The role of comorbidities in chronic myeloid leukemia. Leuk Res 37(7):729–730. doi:10.1016/j.leukres.2013.04.001

    Article  PubMed  Google Scholar 

  • Brunner AM, Campigotto F, Sadrzadeh H, Drapkin BJ, Chen YB, Neuberg DS, Fathi AT (2013) Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis. Cancer 119(14):2620–2629. doi:10.1002/cncr.28106

    Article  PubMed  Google Scholar 

  • Carlhed R, Bojestig M, Wallentin L, Lindstrom G, Peterson A, Aberg C, Lindahl B (2006) Improved adherence to Swedish national guidelines for acute myocardial infarction: the Quality Improvement in Coronary Care (QUICC) study. Am Heart J 152(6):1175–1181. doi:10.1016/j.ahj.2006.07.028

    Article  PubMed  Google Scholar 

  • Chang CS, Lee K, Yang YH, Lin MT, Hsu CN (2011) Estimation of CML incidence: disagreement between national cancer registry and health claims data system in Taiwan. Leuk Res 35(5):e53–e54. doi:10.1016/j.leukres.2010.12.034

    Article  PubMed  Google Scholar 

  • Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383

    Article  CAS  PubMed  Google Scholar 

  • Chen Y, Wang H, Kantarjian H, Cortes J (2013) Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma 54(7):1411–1417. doi:10.3109/10428194.2012.745525

    Article  PubMed  Google Scholar 

  • Corm S, Micol JB, Leroyer A, Daudignon A, Preudhomme C, Poulain B, Bregman B, Oukessou A, Lai J, Facon T (2008) Kinetic of chronic myeloid leukemia (CML) prevalence in Northern France since the introduction of imatinib. J Clin Oncol 26(15S):7088

    Google Scholar 

  • Corm S, Roche L, Micol JB, Coiteux V, Bossard N, Nicolini FE, Iwaz J, Preudhomme C, Roche-Lestienne C, Facon T, Remontet L (2011) Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study. Blood 118(16):4331–4337. doi:10.1182/blood-2011-01-330332

    Article  CAS  PubMed  Google Scholar 

  • Dahlén T, Edgren G, Höglund M, Lambe M, Björkholm M, Sandin F, Själander A, Richter J, Ohm L, Bäck M, Stenke L (2016) Cardiovascular Events Associated with use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population- Based Cohort Study. Ann Int Med 124(21):3134–3134

    Google Scholar 

  • de la Fuente J, Baruchel A, Biondi A, de Bont E, Dresse MF, Suttorp M, Millot F, International BFMGSGCMLC (2014) Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol 167(1):33–47. doi:10.1111/bjh.12977

    Article  PubMed  Google Scholar 

  • Dinmohamed AG, van Norden Y, Visser O, Posthuma EF, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Jongen-Lavrencic M (2015) The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands. Leuk Res 39(2):177–182. doi:10.1016/j.leukres.2014.11.025

    Article  PubMed  Google Scholar 

  • Faber E, Muzik J, Koza V, Demeckova E, Voglova J, Demitrovicova L, Chudej J, Markuljak I, Cmunt E, Kozak T, Tothova E, Jarosova M, Dusek L, Indrak K (2011) Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000–a report from the population-based CAMELIA Registry. Eur J Haematol 87(2):157–168. doi:10.1111/j.1600-0609.2011.01637.x

    Article  PubMed  Google Scholar 

  • Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, Sorensen HT (2011) Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 118(25):6515–6520. doi:10.1182/blood-2011-04-348755

    Article  CAS  PubMed  Google Scholar 

  • Gale RP, Cozen W, Goodman MT, Wang FF, Bernstein L (2000) Decreased chronic lymphocytic leukemia incidence in Asians in Los Angeles County. Leuk Res 24(8):665–669

    Article  CAS  PubMed  Google Scholar 

  • Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, D’Emilio A, Stagno F, le Coutre P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jang E, Reiffers J, Valsecchi MG, Kim DW (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103(7):553–561. doi:10.1093/jnci/djr060

    Article  CAS  PubMed  Google Scholar 

  • Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, Martino B, Pregno P, Rupoli S, Ferrero D, Gherlinzoni F, Montefusco E, Bocchia M, Tiribelli M, Pierri I, Grifoni F, Marzocchi G, Amabile M, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M, Rosti G (2011) Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 117(21):5591–5599. doi:10.1182/blood-2010-12-324228

    Article  CAS  PubMed  Google Scholar 

  • Gunnarsson N, Hoglund M, Stenke L, Wallberg Jonsson S, Sandin F, Bjorkholm M, Dreimane A, Lambe M, Markevarn B, Olsson-Stromberg U, Wadenvik H, Richter J, Sjalander A (2015a) Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia. Blood 126(23):1586–1586. doi: 10.1038/leu.2016.59

    Google Scholar 

  • Gunnarsson N, Stenke L, Hoglund M, Sandin F, Bjorkholm M, Dreimane A, Lambe M, Markevarn B, Olsson-Stromberg U, Richter J, Wadenvik H, Wallvik J, Sjalander A (2015b) Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. Br J Haematol 169(5):683–688. doi:10.1111/bjh.13346

    Article  CAS  PubMed  Google Scholar 

  • Harrison SJ, Johnson PR, Holyoake TL (2004) The Scotland Leukaemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000. Scott Med J 49(3):87–90

    CAS  PubMed  Google Scholar 

  • Heyssel R, Brill AB, Woodbury LA, Nishimura ET, Ghose T, Hoshino T, Yamasaki M (1960) Leukemia in Hiroshima atomic bomb survivors. Blood 15:313–331

    CAS  PubMed  Google Scholar 

  • Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, Costeas P, Mayer J, Indrak K, Everaus H, Koskenvesa P, Guilhot J, Schubert-Fritschle G, Castagnetti F, Di Raimondo F, Lejniece S, Griskevicius L, Thielen N, Sacha T, Hellmann A, Turkina AG, Zaritskey A, Bogdanovic A, Sninska Z, Zupan I, Steegmann JL, Simonsson B, Clark RE, Covelli A, Guidi G, Hehlmann R (2015) The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia 29(6):1336–1343. doi:10.1038/leu.2015.73

    Article  CAS  PubMed  Google Scholar 

  • Hoglund M, Sandin F, Hellstrom K, Bjoreman M, Bjorkholm M, Brune M, Dreimane A, Ekblom M, Lehmann S, Ljungman P, Malm C, Markevarn B, Myhr-Eriksson K, Ohm L, Olsson-Stromberg U, Sjalander A, Wadenvik H, Simonsson B, Stenke L, Richter J (2013) Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood 122(7):1284–1292. doi:10.1182/blood-2013-04-495598

    Article  PubMed  PubMed Central  Google Scholar 

  • Hoglund M, Sandin F, Simonsson B (2015) Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol 94(Suppl 2):S241–S247. doi:10.1007/s00277-015-2314-2

    Article  PubMed  Google Scholar 

  • Huang X, Cortes J, Kantarjian H (2012) Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118(12):3123–3127. doi:10.1002/cncr.26679

    Article  PubMed  PubMed Central  Google Scholar 

  • Juliusson G, Lazarevic V, Horstedt AS, Hagberg O, Hoglund M (2012) Acute myeloid leukemia in the real world: why population-based registries are needed. Blood 119(17):3890–3899. doi:10.1182/blood-2011-12-379008

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kantarjian HM, Fojo T, Mathisen M, Zwelling LA (2013) Cancer drugs in the United States: Justum Pretium–the just price. J Clin Oncol 31(28):3600–3604. doi:10.1200/JCO.2013.49.1845

    Article  PubMed  PubMed Central  Google Scholar 

  • Kim DW, Banavali SD, Bunworasate U, Goh YT, Ganly P, Huang H, Irving I, Jootar S, Goh HG, Koh LP, Li W, Naoe T, Ng SC, Purushotaman V, Reksodiputro H, Shih LY, Tang JL, Tojo A, Wang J, Wong R (2010) Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res 34(11):1459–1471. doi:10.1016/j.leukres.2010.03.033

    Article  PubMed  Google Scholar 

  • Kurtovic-Kozaric A, Hasic A, Radich JP, Bijedic V, Nefic H, Eminovic I, Kurtovic S, Colakovic F, Kozaric M, Vranic S, Bovan NS (2015) The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients. Br J Haematol. doi:10.1111/bjh.13843

    PubMed  Google Scholar 

  • Lauseker M, Hasford J, Pfirrmann M, Hehlmann R, German CMLSG (2014) The impact of health care settings on survival time of patients with chronic myeloid leukemia. Blood 123(16):2494–2496. doi:10.1182/blood-2013-11-539742

    Article  CAS  PubMed  Google Scholar 

  • Matasar MJ, Ritchie EK, Consedine N, Magai C, Neugut AI (2006) Incidence rates of the major leukemia subtypes among US Hispanics, Blacks, and non-Hispanic Whites. Leuk Lymphoma 47(11):2365–2370. doi:10.1080/10428190600799888

    Article  PubMed  Google Scholar 

  • Maynadie M, Girodon F, Manivet-Janoray I, Mounier M, Mugneret F, Bailly F, Favre B, Caillot D, Petrella T, Flesch M, Carli PM (2011) Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d’Or (Burgundy, France). Haematologica 96(1):55–61. doi:10.3324/haematol.2010.026252

    Article  PubMed  Google Scholar 

  • McQuilten ZK, Wood EM, Polizzotto MN, Campbell LJ, Wall M, Curtis DJ, Farrugia H, McNeil JJ, Sundararajan V (2014) Underestimation of myelodysplastic syndrome incidence by cancer registries: results from a population-based data linkage study. Cancer 120(11):1686–1694. doi:10.1002/cncr.28641

    Article  PubMed  Google Scholar 

  • Mohammadi M, Cao Y, Glimelius I, Bottai M, Eloranta S, Smedby KE (2015) The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma – a Swedish population-based study. BMC Cancer 15:850. doi:10.1186/s12885-015-1857-x

    Article  PubMed  PubMed Central  Google Scholar 

  • Musselman JR, Blair CK, Cerhan JR, Nguyen P, Hirsch B, Ross JA (2013) Risk of adult acute and chronic myeloid leukemia with cigarette smoking and cessation. Cancer Epidemiol 37(4):410–6

    Google Scholar 

  • Ohm L, Lundqvist A, Dickman P, Hoglund M, Persson U, Stenke L, Steen Carlsson K, Bjorkholm M (2014) Real-world cost-effectiveness in chronic myeloid leukaemia: the price of success during four decades of development from non-targeted treatment to imatinib. Leuk Lymphoma :1–16. doi:10.3109/10428194.2014.953141

    Google Scholar 

  • Osca-Gelis G, Puig-Vives M, Saez M, Gallardo D, Lloveras N, Marcos-Gragera R (2013) Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain. Haematologica 98(8):e95–e97. doi:10.3324/haematol.2013.084061

    Article  PubMed  PubMed Central  Google Scholar 

  • Parkin DM, Bray F (2009) Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness Eur J Cancer 45(5):756–764. doi:10.1016/j.ejca.2008.11.033

    Article  PubMed  Google Scholar 

  • Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, Hoffmann VS, Castagnetti F, Hasford J, Hehlmann R, Simonsson B (2015) Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. doi:10.1038/leu.2015.261

    PubMed Central  Google Scholar 

  • Proetel U, Pletsch N, Lauseker M, Muller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Muller L, Hanel M, Link H, Hertenstein B, Pfirrman M, Hochhaus A, Hasford J, Hehlmann R, Saussele S, German Chronic Myeloid Leukemia Study G, Schweizerische Arbeitsgemeinschaft fur Klinische K (2014) Older patients with chronic myeloid leukemia (>/=65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Ann Hematol 93(7):1167–1176. doi:10.1007/s00277-014-2041-0

    Google Scholar 

  • Pulte D, Gondos A, Redaniel MT, Brenner H (2011) Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries. Oncologist 16(5):663–671. doi:10.1634/theoncologist.2010-0393

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Radivoyevitch T, Jankovic GM, Tiu RV, Saunthararajah Y, Jackson RC, Hlatky LR, Gale RP, Sachs RK (2014) Sex differences in the incidence of chronic myeloid leukemia. Radiat Environ Biophys 53(1):55–63. doi:10.1007/s00411-013-0507-4

    Article  PubMed  Google Scholar 

  • Rebora P, Czene K, Antolini L, Gambacorti Passerini C, Reilly M, Valsecchi MG (2010) Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study. Am J Epidemiol 172(9):1028–1033. doi:10.1093/aje/kwq262

    Article  PubMed  Google Scholar 

  • Rego MN, Metze K, Lorand-Metze I (2015) Low educational level but not low income impairs the achievement of cytogenetic remission in chronic myeloid leukemia patients treated with imatinib in Brazil. Clinics (Sao Paulo) 70(5):322–325. doi:10.6061/clinics/2015(05)03

    Article  Google Scholar 

  • Rohrbacher M, Hasford J (2009) Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol 22(3):295–302. doi:10.1016/j.beha.2009.07.007

    Article  PubMed  Google Scholar 

  • Rohrbacher M, Berger U, Hochhaus A, Metzgeroth G, Adam K, Lahaye T, Saussele S, Muller MC, Hasford J, Heimpel H, Hehlmann R (2009) Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 23(3):602–604. doi:10.1038/leu.2008.245

    Article  CAS  PubMed  Google Scholar 

  • SEER (2015) SEER. Cancer Statistics Review 1975-2012. http://seer.cancer.gov

  • Shah BK, Ghimire KB (2013) Chronic myeloid leukemia survival in older population in the United States. Leuk Lymphoma. doi:10.3109/10428194.2013.775435

    PubMed Central  Google Scholar 

  • Smith A, Roman E, Howell D, Jones R, Patmore R, Jack A, Haematological Malignancy Research N (2010) The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br J Haematol 148(5):739–753. doi:10.1111/j.1365-2141.2009.08010.x

    Article  PubMed  Google Scholar 

  • Smith AG, Painter D, Howell DA, Evans P, Smith G, Patmore R, Jack A, Roman E (2014) Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort. BMJ Open 4(1), e004266. doi:10.1136/bmjopen-2013-004266

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Socialstyrelsen (2015) Cancer incidence in Sweden 2014. https://www.socialstyrelsen.se/english

  • Storm HH, Michelsen EV, Clemmensen IH, Pihl J (1997) The Danish Cancer Registry–history, content, quality and use. Dan Med Bull 44(5):535–539

    CAS  PubMed  Google Scholar 

  • Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L (2015) Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood 126(1):42–9

    Google Scholar 

  • Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, O’Brien S, Cortes J (2011) Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 118(16):4353–4358. doi:10.1182/blood-2011-06-362889

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Visser O, Trama A, Maynadie M, Stiller C, Marcos-Gragera R, De Angelis R, Mallone S, Tereanu C, Allemani C, Ricardi U, Schouten HC, Group RW (2012) Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 48(17):3257–3266. doi:10.1016/j.ejca.2012.05.024

    Google Scholar 

  • Voglova J, Muzik J, Faber E, Zackova D, Klamova H, Steinerova K, Michalovicova Z, Demitrovicova L, Cmunt E, Novakova L, Tothova E, Belohlavkova P, Mayer J, Indrak K (2011) Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. Neoplasma 58(3):256–262

    Article  CAS  PubMed  Google Scholar 

  • Wiggins CL, Harlan LC, Nelson HE, Stevens JL, Willman CL, Libby EN, Hromas RA (2010) Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. Am J Med 123 (8):764.e761–769. doi:10.1016/j.amjmed.2010.03.018

    Google Scholar 

Download references

Acknowledgements

The authors appreciate the work of all clinicians reporting all newly diagnosed cases of CML to the Swedish CML registry.

Conflict of Interest Disclosures

Nothing to disclose

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Medical Science, Uppsala University Hospital, Uppsala, SE-751 85, Sweden

    Martin Höglund MD, PhD & Bengt Simonsson

  2. Regional Cancer Centre, University Hospital, Uppsala-Örebro, Sweden

    Fredrik Sandin

Authors
  1. Martin Höglund MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fredrik Sandin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bengt Simonsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Höglund MD, PhD .

Editor information

Editors and Affiliations

  1. Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany

    Rüdiger Hehlmann

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Höglund, M., Sandin, F., Simonsson, B. (2016). Epidemiology of Chronic Myeloid Leukemia. In: Hehlmann, R. (eds) Chronic Myeloid Leukemia. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-33198-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-33198-0_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-33197-3

  • Online ISBN: 978-3-319-33198-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation